Nascent Biotech Inc. (NBIO) is a publicly traded company in the Unknown sector. Across all available filings, 5 corporate insiders have executed 125 transactions totaling $3.3M, demonstrating a bullish sentiment with $3.3M in net insider flow. The most recent transaction on Mar 31, 2024 involved a transaction of 27,100 shares valued at $4.9K.
No significant insider buying has been recorded for NBIO in the recent period.
No significant insider selling has been recorded for NBIO in the recent period.
Based on recent SEC filings, insider sentiment for NBIO is bullish with an Insider Alignment Score of 100/100 and a net flow of $3.3M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Nascent Biotech Inc. (NBIO) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 5 insiders are actively trading NBIO stock, having executed 125 transactions in the past 90 days. The most active insider is Sean Carrick (Executive), who has made 37 transactions totaling $5.1M.
Get notified when executives and directors at NBIO file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Mar 31, 2024 | John Karas Douglas | Executive | Other | 27,100 | $0.18 | $4.9K | |
| Mar 31, 2024 | Carrick Sean | Executive | Other | 225,000 | $0.18 | $40.5K | |
| Mar 31, 2024 | Thomas Holden Lowell | Executive | Other | 112,500 | $0.18 | $20.3K | |
| Dec 29, 2023 | John Karas Douglas | Executive | Other | 28,935 | $0.18 | $5.2K | |
| Dec 29, 2023 | Thomas Holden Lowell | Executive | Other | 119,650 | $0.17 | $20.3K | |
| Dec 29, 2023 | Carrick Sean | Executive | Other | 239,300 | $0.17 | $40.7K | |
| Sep 29, 2023 | Carrick Sean | Executive | Other | 2,772,600 | $0.13 | $360.4K | |
| Sep 29, 2023 | Thomas Holden Lowell | Executive | Other | 1,386,300 | $0.13 | $180.2K | |
| Sep 29, 2023 | John Karas Douglas | Executive | Other | 39,750 | $0.13 | $5.2K | |
| Jun 29, 2023 | Thomas Holden Lowell | Executive | Gift | 700,000 | $0.05 | $35.0K | |
| Jun 29, 2023 | Carrick Sean | Executive | Gift | 960,000 | $0.05 | $48.0K | |
| Jun 7, 2023 | Thomas Holden Lowell | Executive | Purchase | 130,000 | $0.04 | $5.2K | |
| Mar 31, 2023 | Carrick Sean | Executive | Other | 1,167,000 | $0.06 | $70.0K | |
| Mar 31, 2023 | Thomas Holden Lowell | Executive | Other | 581,000 | $0.06 | $34.9K | |
| Mar 31, 2023 | John Karas Douglas | Executive | Other | 89,285 | $0.06 | $5.4K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Other(J) | 104 | $7.4M | 65.9% |
Purchase(P) | 11 | $3.3M | 29.3% |
Gift(G) | 6 | $393.0K | 3.5% |
Award(A) | 3 | $142.1K | 1.3% |
Sale(S) | 1 | $1.3K | 0.0% |
Insiders at Nascent Biotech Inc. are accumulating shares at an accelerated pace. With 5 insiders making 125 transactions totaling $3.3M in purchases versus $1.3K in sales, the net buying activity of $3.3M signals strong executive confidence. Sean Carrick (Executive) leads the buying activity with $5.1M in transactions across all time.